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their recommendations for the implementation, the target-group, the rescreening
interval and the primary screening methods of the programs proposed, and to
recommend the social insurance reimbursement level. RESULTS:Of the 33 experts
invited, 26 (78%) accepted to participate. The vast majority of them supported the
implementation of an NSP for breast cancer, cervical cancer, colorectal cancer,
vascular risk and abdominal aortic aneurysm. Both the rescreening interval and
the primary screening method of each of the programs were considered adequately
effective. The biggest debate was focused on the target-group of the colorectal
cancer and the abdominal aortic aneurysm program. All of the experts argued that
social insurance should fully reimburse the programs for the individuals that fulfill
the eligibility criteria. Otherwise the cost should be borne by the individual, accord-
ing to the 77% of the panelists. 68% of the experts argued that when the eligibility
criteria are not fullfiled but the individual is referred by a general practitioner or a
specialist for screening, social insurance should partly reimburse the cost.
CONCLUSIONS: Despite any debates especially on the target-group of the pro-
grams, all of the programs were deemed necessary, stressing the need for orga-
nized screening in order to reduce mortality and morbidity from certain conditions
and to optimize the allocation of resources invested in secondary prevention
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OBJECTIVES: To systematically review the literature for methods of estimating the
costs of palliative care and to assess which costs are included in palliative care.
METHODS: Preliminary scoping of health technology assessment appraisals iden-
tified high degree of heterogeneity in how palliative care is defined, in terms of the
type of care, and the models and settings of delivery. To focus the review, patients
with metastatic renal cell carcinoma (mRCC) were chosen as the reference popu-
lation, in keeping with the PICO (population, indication, comparison, outcome)
approach to formulating research questions. Relevant search terms were identified
and searches conducted in EMBASE, MEDLINE, Cochrane library and Econlit. Re-
sults were filtered using pre-specified selection criteria and data extracted into a
pre-defined template. RESULTS: Without a specified patient population, database
searches identified almost 17,000 records; mRCC focussed searches identified 1,172
records. From mRCC searches 66 full text publications were assessed and only 17
met pre-defined inclusion criteria. Of these publications, nine assessed surgery
costs; five were cost-effectiveness assessments; and three assessed burden of dis-
ease. Cost data collected was largely based on expert opinion and country-specific
assumptions (with potential bias) making generalisation difficult. Notable levels of
heterogeneity between the included publications (publication type, year, country
and perspective) precluded consistent, qualitative synthesis of the data.
CONCLUSIONS: Despite focussing on a specific disease population, high levels of
heterogeneity in the reporting and study of palliative care, in terms of setting and
delivery, prevented a robust interpretation of the data. A key driver of this hetero-
geneity may be the fact that palliative care is delivered in a variety of settings, using
diverse models of care. Evidence-based assessments of costs of palliative care
present methodological challenges. Therefore, we see a need for agreement on the
definitions and parameters of palliative care, which would greatly assist future
decision making.
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OBJECTIVES: Australia has the highest incidence of melanoma in the world, how-
ever little published information exists regarding treatment patterns. A study was
undertaken to define current treatment options offered to Australian patients.
METHODS:A survey was developed from interviews with 7 scientific experts treat-
ing melanoma in Australia. Algorithms outlining referral and treatment patterns
across all stages of melanoma were derived and validated by dermatologists and
general surgeons for early stage and medical oncologists for later stage disease.
RESULTS: A total of 115 oncologists were identified as treating melanoma in Aus-
tralia and 26% of those responded. In addition, a sample of 40 dermatologists and
surgeons were contacted and 43% of those participated. Results demonstrated that
nearly all patients with local or locoregional melanomas undergo radical excision
of their primary lesion; whereas 73.1% of patients with metastatic melanoma have
their primary lesion excised. For metastatic disease, the majority of oncologists
reported that current 1st line chemotherapy is dacarbazine (DTIC) (85%) or fote-
mustine (77%), although a large percentage also reported enrolling patients in clin-
ical trials (73%). Nine oncologists (36%) surveyed indicated that they expect overall
survival (OS) of 7-9 months after initiation of 1st line chemotherapy. Oncologists
also reported that 48% of patients who relapse after 1st line therapy receive 2nd
line therapy, of which enrollment into a clinical trial (69%) or treatment with fote-
mustine (62%) are the most common treatment options. Approximately half (48%)
of oncologists surveyed expect OS in 2nd line to be 3-6 months. The most common
sites for development of metastases were reported to be lung (48.0%), liver (47.6%)
and brain (38.0%). CONCLUSIONS: To our knowledge, this is the first survey con-
ducted to understand melanoma treatment patterns in Australia. This study pro-
vides information for evidence-based decision makers to understand how health
resources are utilised in the treatment of melanoma in Australia.
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OBJECTIVES: Access to innovative medicines is sometimes challenging due to is-
sues related to affordability, attributable at least in part to the heterogeneity and
design of health insurance coverage. A support program (Program) to help patients
requesting assistance in accessing oral oncology agents was evaluated to deter-
mine if it facilitated their access to medication.METHODS: Anonymized data from
a random sample of patients enrolling in the Program in 2008-2009 and a random
sample of control patients from Risk Evaluation and Mitigation Strategies (REMS)
programs for lenalidomide and thalidomide were analyzed. Specifically, patient
characteristics, type of assistance provided, and dispensing outcomes (proportion
successfully dispensed medication, time from prescription authorization to first
dispense, reason for non-dispense, and proportion of Program patients seeking
further assistance following their initial request) were assessed. RESULTS: A ran-
dom sample of 1000 Program and 1000 control patients was evaluated. Most pa-
tients had a primary diagnosis of multiple myeloma or of myelosdysplastic syn-
dromes. Despite the expressed need for assistance in accessing medication among
the Program patients, the percentage of Program patients receiving medication
compared with patients in the control group was not statistically different (89% vs.
91%, respectively; p 0.270), with a difference in median time to dispense of 3 days.
Ninety-two percent of Program patients successfully obtained durable access to
oral medication. CONCLUSIONS: The results suggest that a support program for
patients needing assistance in a complex health insurance environment can effec-
tively achieve a goal of helping them to obtain access to therapies prescribed by
their physicians. Research should be conducted to better understand which ele-
ments of such programs are most valuable to patients, and therefore would be
considered best practices for such programs.
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OBJECTIVES: As the potential role of genetic testing in disease prevention and
management grows, so does concern about differences in uptake of genetic testing
across social and racial groups. Characteristics of how genetic tests are delivered
may influence willingness to undergo testing and potentially alter disparities in
testing. METHODS: Conjoint analysis study of the effect of three characteristics of
genetic test delivery on willingness to undergo genetic testing for cancer risk. Data
were collected using a random digit dialing survey of 337 individuals living in the
US. Measures included conjoint scenarios, health care system distrust (values and
competence subscales), health insurance coverage, and sociodemographic charac-
teristics. Three attributes were studied: disclosure of test results to the health
insurer, provision of the test by a specialist or primary care doctor, race specific or
race neutral marketing. RESULTS: In adjusted analyses, disclosure of test results to
insurers, having to get the test from a specialist, and race specific marketing were
all inversely associated with willingness to undergo the genetic test, with the great-
est effect for the disclosure attribute. Racial differences in willingness were not
statistically significant (p0.07) and the effect of the attributes on willingness to
undergo testing did not vary by patient race. However, the decrease in willingness
with insurance disclosure was greater among individuals with high values distrust
(p0.03) and the decrease in willingness to undergo testing from specialist access
was smaller among individuals with high competence distrust (p0.03).
CONCLUSIONS: Several potentially modifiable characteristics of how genetic tests
are delivered are associated with willingness to undergo testing. The effect of two
of these vary according to the level of health care system distrust, suggesting that
policy decisions about delivery of genetic testing may influence differences in up-
take across patient subgroups defined by levels of distrust rather than by race.
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OBJECTIVES: Lung cancer is the most common cause of cancer mortality in Europe.
Gefitinib and erlotinib are two epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) registered for patients with non–small-cell lung cancer
(NSCLC). Patients with a positive EGFR-mutation benefit from first line treatment
with EGFR-TKIs. However, since worse outcomes are observed among patients
without the mutation, testing is crucial. Our study aims to investigate the use of
diagnostics and treatment with EGFR-TKI of patients with NSCLC in daily practice.
METHODS: We sent a semi-structured questionnaire to physicians and laborato-
ries about EGFR-mutation tests and treatment strategies. Furthermore, sales num-
bers of gefitinib and erlotinib were obtained to calculate the number of patients
treated with EGFR-TKI. RESULTS: Response covered more than two third of the
Dutch lung cancer population. Approximately 70% of the patients, which should
have been tested for EGFR-mutation, were tested. Sub-analyses revealed large re-
A463V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
